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ABSTRACT
Background: Whereas the Fiji government provides all aspects of mental health care services
free of charge to its citizens, many schizophrenics have failed to respond to classical
antipsychotic drugs.
Objective: To assess the efficacy and safety of olanzapine among various patients with severe
psychiatric disorders.
Setting: Naturalistic setting.
Design:  Descriptive study.
Measurements: Outcome was based on reduction of symptoms on the PANSS (≥ 40%) and
CGI shift to 1-3.
Subjects: The were 64 patients (30 males) aged 17-77 years. Thirty six (56.3%) had
schizophrenia, eight mania, ten severe depression, four obsessive compulsive disorder
(OCD), one each had schizo-affective and delusional disorders, while the remaining had
chronic brain diseases.
Results: At weeks 3, 8,12, the proportion of subjects with 40% improvement was 60.6%,
79.9%, and 76.8%, respectively. Positive and negative symptoms improved. Thirteen
(48.1%) of the 27 long-stay treatment - resistant schizophrenics achieved clinical recovery
at eight weeks. All with primary diagnosis of severe depression and mania achieved full
clinical recovery (mostly within two weeks). Two OCD cases achieved clinical recovery at
week eight.
Conclusion: Olanzapine was safe for all categories of patients. There was not a single case of
extrapyramidal reaction among subjects who did not have it pre-treatment; and the drug
was safe in a suicidal overdose of 205mg. Most patients experienced weight gain; two
adolescent girls had temporary amenorrhoea and one subject had transient rise in liver
transaminases which normalised without discountinuing the drug.
INTRODUCTION
After over four decades of clinical experience of use
of the classical or typical antipsychotic drugs, psychiatrists
are challenged by the fact that 30-50% of schizophrenics
do not significantly benefit from these drugs, and there are
adverse effects, some of which could be irreversible(1).
This situation serves as a compelling motivation to seek
treatment alternative.
Clozapine was reintroduced into the
psychopharmacology market in the late 1980s as the first
to fulfill the characteristics of what has recently become
known as “atypical antipsychotic” drugs, namely, broader
efficacy than the older drugs; a lower incidence of
extrapyramidal symptoms; minimal perturbation of
prolaction levels; and therapeutic efficacy among non -
responders to conventional neuroleptics(2).
Such a therapeutic advance should have substantial
relevance for the societal costs, personal suffering and
mortality that characterise schizophrenia(3) .
The problems with clozapine are, the danger of
potentially fatal leucopaenia, the significant lowering of
seizure threshold and sialorrhoea.
In the Fiji Islands, a South Pacific developing country
of some 800,000 mixed race people, of whom the
indigenous race claims Tanzanian (African) origin, mental
health care delivery is free, and the classical antipsychotic
drugs are abundantly available. By early 1997, the major
challenge to clinical psychiatry was that at least one - third
of admissions in the nation’s only psychiatric hospital
(190 beds) were neuroleptic treatment - resistant long-stay
schizophrenics. The Ministry of Health therefore agreed
to purchase some quantity of the new atypical antipsychotic
drug, Olanzapine (OLZ), for a 6-8 week efficacy and
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safety trial, with a view to seeing whether a significant
proportion of these schizophrenics could achieve enough
remission of symptoms to be discharged home.
OLZ is a thienobenzodiazepine structurally related to
clozapine, with relatively greater binding affinity for 5-
HT2 compared to D2 receptors. The compound has a
broad receptor profile, that is, it is pleotropic.
As at February, 1995, OLZ had been investigated in
50 studies in 22 countries, resulting in a total of 3139
persons having been exposed to at least one dose of
OLZ(4).
Since then, there has been a plethora of publications,
making OLZ one of the most rigorously investigated of
new drugs(4-8). All these studies were unanimous in
upholding the credentials of OLZ as fulfilling the
requirements of belonging to the group of “atypical”
antipsychotic drugs(9). In addition, evidence has now
emerged indicating that the drug also has impressive anti-
manic(10) and direct antidepressant effects(11,12),
especially among schizophrenics(3), while improving
cognitive functioning(11) . OLZ has been shown to be
efficacious in treatment - resistant schizophrenics(12,13),
especially at 40-60 mg daily dosage(14).
This is a general descriptive study, not a controlled
double - blind study. The aims of the study were, to assess
the efficacy and safety of OLZ among the variety of
patients with severe psychiatric states that patronise our
centre and were treated in the usual clinical care
(naturalistic) setting. Although the initial mandate
concerned treatment - resistant long-stay schizophrenics,
other patients were included with severe depression and
suicidal behaviour who either refused electroconvulsive
therapy (ECT) or had heart disease; as well as manic
patients who had extrapyramidal reactions to classical
neuroleptics and obsessional (OCD) patients who had
failed to respond to standard treatments.
The naturalistic setting of the study allowed for the
inclusion of such a wide variety of patient groups.
MATERIALS AND METHODS
Location and instruments: The study took place at St. Giles
Psychiatric Hospital, Suva, Fiji, from late January, 1997 to mid-
April, 1998. All the subjects involved in the study were the
author’s patients and were all personally assessed by him at
intake, and then at weeks 3, 6, 8, 10 and 12 using the following
instruments: (i) The 30-item Positive and Negative Syndrome
Scale (PANSS) (15), rated along a scale of severity that ranged
from 1 (normal) to 7 (extreme). This instrument contains the
main symptoms of schizophrenia and can be used to assess
severity of mania, depression, anxiety and OCD; (ii) the Clinical
Global Impression (CGI) scale, for a global assessment of
severity of illness at intervals, also rated on a 7-point scale of, l
(normal), 2 (minimal or borderline ill), 3 (mild), 4 (moderately
ill), 5 (markedly ill) 6 (severely ill) to 7 (among the most
extremely ill patients) (16); (iii) Parkinsonism (17), akathisia
(18) and tardive dyskinesia (16), were also assessed; (iv) The
Hamilton Depression Rating Scale (HDRS) was applied to 10
subjects with a primary diagnosis of severe depression; and one
with obsessive compulsive disorder (OCD); (v) side effects were
specifically enquired into; (vi) haematological and biochemical
tests, pre - olz, at three weeks and six; (vii) the Yale-Brown
Obsessive Compulsive Scale (Y - BOCS) was applied to four
subjects with OCD, at some time after olz had been initiated.
Subjects: There were three broad groups of patients, namely:
(i) twenty seven long-stay treatment resistant schizophrenics;
(ii) fifteen treatment resistant patients who had spent less than
one-year in hospital or were out-patients and; (iii) twenty two
acutely ill subjects (including schizophrenics, depressed and
manic patients) who had not yet received adequate neuroleptic
treatment for the current episode. All patients and relatives freely
consented to participate in the study after the objectives were
explained to them by the author.
Definition of treatment resistance and efficacy measures: A
neuroleptic treatment resistant schizophrenic (NTRS) was
operationally defined as one who had failed to respond to at least
800mg chlorpromazine equivalent daily dosage for at least the
past one year. Efficacy of treatment was defined by the following
measures: a CGI scale score of 2 or 3 for the NTRS cases; and one
or two for all the acutely ill cases; for all cases, a forty percent
reduction in PANSS score by the sixth to eighth week of
treatment (3); for the depressed patients, a HDRS Scale Score of
less than 10 by the sixth week of treatment and; for the OCD
cases, an admission by the patient of significant freedom from
symptoms.
Dosage: The initial starting daily dosage for NTRS cases,
acutely ill schizophrenics and manic subjects was 15 - 20mg. In
addition, six NTRS received 30mg daily for four weeks, after a
12-week period of 20mg in which they had not shown significant
improvement. Patients with severe depression were treated mostly
with 10-15mg nightly dose. The OCD cases received 5-15mg
daily.
RESULTS
Demographic characteristics: The sample consisted
of 30 males (mean age, 39.6 ± 13.4) and 34 females (39.2
±14.3 years) (age range, 17-77, mean, 39.4 ±13.8yrs).
There were 26(40.6%) indigenous Fijians and 31(48.4%)
Indians, with other races (Chinese, European) constituting
9.9% of the sample.
Clinical characteristics: Subjects fulfilled the
American DSM-IV criteria for the diagnosis of
schizophrenia (36 or 56.3%), Bipolar I disorder, manic
phase (8 or 12.5%), severe depression (10 or 15.6%); OCD
(4 or 6.25%); while one each (1.6% x 2) had schizoaffective
disorder and delusional disorder, respectively. The
remaining subjects had brain diseases, in addition to severe
mental disorder. This group included an elderly (77-yr old)
lady who had previously suffered two episodes of
cerebrovascular accident; two subjects who had frequent
episodes of convulsions from childhood; and one subject
who had mild mental retardation. One depressed patient
was on follow up treatment for heart failure.
There were 51(79.7%) in-patients, and 13 (20.3%)
out-patients.
On the whole, 27 (43.8%) subjects were long-stay
neuroleptic treatment-resistant schizophrenic cases, having
been continuously on admission for over one year and
experienced no improvement inspite of adequate
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neuroleptic treatment and ECT. Another 15 (21.9%)
subjects were also treatment resistant (NTR) but were
either out-patients or had stayed in hospital for less than
one year. This group included schizophrenics, OCD cases,
and one epileptic and mental retard with schizophrenic
symptoms. The remaining 22 (34.4%) subjects were acutely
ill, had not been exhaustively treated with the older methods
and included acutely ill schizophrenics, the affective
disorder cases, two OCD cases and delusional disorder.
The hospital provided the drug free for 33 (51.6%)
subjects, while relatives bought it for 24 (37.5%). For the
remaining seven (10.9%), hospital supplemented the supply
from relatives.
Efficacy measures: Number of subjects remaining in
the trial: Sixty (93.8%) completed eight weeks of active
phase of treatment. The remaining four consisted of three
depressed patients who had responded very well and one
non-responding acute schizophrenic whose relatives
43.6% achieved this level of improvement at the sixth
week; while from the eighth week onward, the median and
mode scores for percentage improvement were consistently
above 50.0.
Change in Psychopathological Symptoms Scores
(PANSS):  It is to be noted that, as conceptualised, negative
symptoms are features of schizophrenia; and while severely
depressed patients would also have a lot of these symptoms,
they do not characterise mania and OCD. Schizophrenics
and the depressed showed highly significant (almost one
- half shifts in mean scores) changes in negative symptoms
scores from the third week of assessment; and this was
maintained throughout the active phase of the study (e.g
for schizophrenics, from 26.7 through 15.2 at week 3, to
12.6 at week 10; for depressed patients, from 36.4, through
12.6 at week 3, to 9.0 or no pathology at week 10). Similar
sustained remarkable reductions in positive symptoms
scores were also evident.
Table 1
Overview of total PANSS scores at intervals
No. Interval of assessment Range Mean SD Median Mode
1. Pre-OLZ (N = 64) 44 - 158 86.35 28.7 79.0 57.0
2. Week 3 (N = 64) 30 - 95 46.3 17.2 39.5 30.0
3. Week 6 (N = 62) 30 - 93 40.5 15.6 32.0 30.0
4. Week 8 (N = 60) 30 - 95 40.0 15.6 31.0 30.0
5. Week 10 (N = 51) 30 - 101 38.8 14.1 31.0 30.0
6. Week 12 (N = 43) 30 - 101 40.8 16.2 32.0 30.0
7. Week 14 (N = 25) 30 - 66 36.9 11.6 31.0 30.0
8. Week 16 (N = 25) 30 - 62 35.9 10.8 31.0 30.0
9. Week 18 (N = 15) 30 - 56 34.0 8.4 31.0 31.0
From the third week, 58.4% of schizophrenics had
experienced at least 40% reduction in PANSS scores; and
by the tenth week, the proportion experiencing over 40%
of improvement had increased to 74.1%. When we use the
more conservative yardstick of 50% of reduction of
symptoms, the proportion of schizophrenics experiencing
this level of improvement increased from 35.2% at the
third week, to 53.2% at the tenth week. All the manic and
depressed patients experienced over 40% improvement
from week three.
Significant differences in  psychopathological
symptom scores: At the pre-olz level, the tendency for
higher symptom severity among depressed patients (93.6
± 30.2) and schizophrenics (84.3 ± 29.9) than manic and
OCD cases did not reach statistical significance (F =2.0, p
= 0.07). But at the third week, depressed patients showed
withdrew consent. Majority completed at least 12 weeks
of trial.
Total PANSS Scores: Overview: Table 1 shows that
when taken as a whole, this group of patients showed a
rapid reduction of psychopathological symptoms within
three weeks of treatment, with almost a halving of the
group’s total mean score (86.3 - 46.3). Subsequently, the
mean score fell fairly consistently to 40.8 at week 12. The
median and mode show that from the sixth week of trial,
the commonest individual scores (30-32) were rather
close to the minimum score on the PANSS.
From the third week, the proportion of subjects with
over 40% improvement in psychopathology increased
from 60.6% through 79.9% at the eighth week and was
76.8% at the twelfth week. Even when we use the more
conservative yardstick of 50% improvement we find that
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Table 2
Overview of percentage improvement in psychopathological symptoms scores (ie decrease in PANSS/BPRS scores) at intervals of assessment for
neuroleptic treatment response groups
Interval of Neuroleptic response % Change in PANSS score
assessment Group(No. of subjects)  Range <0 1-19 20-25 26-29  30-39 40-49 50-59 >60
At Week 3 1.  Long stay resistant
(N = 27) -5 to 68 1 (3.7) 4 (14.8) 1 (3.7) 1 (3.7) 5 (18.5) 8 (29.6) 4 (14.8) 3 (11.1)
2.  Short stay resistant
(N= 15) -5 to 65 1 (6.7) 1 (6.7) - 2 (13.3) 1 (6.7) 4 (26.7) 4 (26.7) 1 (6.7)
3.  Acutely ill (N = 22) 0 - 74 - - - - 3 (13.6) 5 (27.3) 9  (40.9) 5 (27.3)
At Week 6 1.  Long Stay (N = 27) -3 to 75 1 (3.7) 2 (7.4) 1 (3.7) 1 (3.7) 4 (14.8) 8 (29.6) 5 (18.5) 5 (18.5)
2.  Short Stay (N = 14) 0 - 68 - - - 1 (7.1) 1 (7.1) 4 (28.6) 3 (21.4) -
3.  Acutely ill (N = 22) 0 - 78 - - - - - 4 (18.2) 7 (31.8) 10 (45.5)
At Week 8 1.  Long Stay (N = 27) -3 to 74 1 (3.7) 2 (7.4) - - 6 (22.2) 6 (22.2) 7 (28.9) 5 (18.5)
2.  Short Stay (N = 13) 0 - 77 - - - 1.(7.7) 1 (7.7) 3 (23.0) 2 (15.4) 6. (46.2)
3.  Acutely ill (N = 20) -4 to 77 1(5) - - - - 2 (10) 8 (409) 9 (45)
At Week 10 1.  Long Stay (N = 26) -1 to 79 1 (3.8) 1 (3.8) - - 5 (19.2) 7 (26.9) 5 (19.2) 7 (26.9)
2.  Short Stay (N = 10) 0 - 77 - - - 1 (10) 1 (10) 1 (10) 2 (20) 5 (50)
3.  Acutely ill (N = 15) 0-78 - 1 (6.7) - - - - 6 (40) 8 (53.3)
At Week 12 1.  Long Stay (N = 22) -1 to 79 1 (4.5) 1 (4.5) - - 5 (22.7) 6 (27.3) 5 (22.7) 4 (18.2)
2.  Short Stay (N = 9) 0 - 75 - - - 1 (11.1) 1 (11.1) 1 (11.1) 2 (22.2) 4 (44.4)
3.  Acutely ill (N = 12) 0 -77 - 1 (8.3 - - - - 5 (41.7) 6 (50.0)
Table 3
Response to olanzapine according to neuroleptic treatment response status (NTRS) at intervals of assessment, using the clinical global
impression scale
Interval of NTRS status Clinical Global Impression
assessment 1 2 3 4 5 6 7
A. Pre-OLZ 1. Long stay resistant (N=27) – – – – 4 (14.8) 4 (14.8) 19 (70.3)
2. Short stay resistant – – – 2 (13.3) 4 (16.7) 6 (40.0) 6 (40.0)
3. Acutely III (N=22) – – – 3 (13.6) 6 (27.3) 4 (18.2) 9 (40.9)
B. Week 3 1. Long stay (N = 27) 2 (7.4) 6 (22.2) 6 (22.2) 6 (22.2) 4 (14.8) 3 (11.1) –
2. Short stay (N = 15) 4 (26.7) 1 (6.7) 3 (20.0) 5 (33.3) - 1 (6.7) 1 (6.7)
3. Acutely ill (N = 22) 8 (36.4) 7 (31.8) 6 (27.3) - 1 (4.5) - -
C. Week 6 1. Long stay (N = 27) 4 (14.8) 9 (33.3) 2 (7.4) 5 (18.5) 4 (14.8) 1 (3.7) 2 (7.4)
2. Short stay (N= 14) 5 (35.7) 4 (28.6) 2 (14.2) 2 (14.2) - 1 (7.1) –
3. Acuteiy ill (N = 22) 19 (86.4) 2 (9.1) - 1 (4.5) - -
D. Week 8 1. Long stay (N = 27) 7 (25.9) 6 (22.2) 5 (18.5) 3 (11.1) 4 (14.8) - 2 (7.4)
2. Short stay (N = 13) 4 (30.7) 6 (46.2) - 2 (15.4) - 1 (7.7) –
3. Acutely ill (N = 20) 17 (85.0) 1 (5.0) 1 (5.0) - - 1 (5.0)
E. Week 10 1. Long stay (N = 26) 6 (23.1) 8 (30.8) 3 (11.5) 4 (15.4) 3 (11.5) - 2 (7.7)
2. Short stay (N = 10) 3 (30.0) 4 (40.0) - 2 (20.0) - 1 (10.0) –
3. Acutely ill (N = 15) 13 (86.7) - 1 (6.7) 1 (6.7) - - -
F. Week 12 1. Long stay (N = 22) 5 (22.7) 4 (18.2) 4 (18.2) 4 (18.2) 2 (9.1) 1 (4.5) 2 (9.1)
2. Short stay(N=9) 2 (22.2) 4 (44.4) - 2 (22.2) - 1 (11.1) –
3. Acutely ill (N = 12) 10 (83.3) - - 1 (8.3) 1 (8.3) - -
significantly higher percentage improvement than
schizophrenics, for total PANSS symptoms scores change
(F = 2.4; p = 0.03) and negative symptoms scores change
(F = 3.8, p = 0.0019). Of the four OCD cases, at the eighth
week, two had achieved full clinical recovery, one had
moderate severity of symptoms (CGI = 4), while one was
treatment resistant.
Change in Psychopathological Symptom Scores
(PANSS) for Neuroleptic Treatment Response Groups
(Tables 2 and 3): The three neuroleptic treatment response
groups showed rapid reduction of symptoms severity.
Table 2 shows that acutely ill patients had much
higher proportions of subjects with over 40% improvement
in symptoms, with this trend reaching significance at the
third and sixth weeks. (F = 8.2, p = 0.0007). From the
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eighth week, however, although the long-stays had
significantly higher PANSS and positive symptoms scores
than the acutely ill at that point (F = 3.6,p = 0.03), there was
no significant differences in mean percentage reduction of
all types of symptoms across the three groups, upto  the
twelfth week.
The tendency for the acutely ill to show higher mean
reduction in symptoms severity than the short stays reached
significance for positive symptoms at the third (F = 4.8, p
= 0.01) and sixth weeks (F = 4.1, p = 0.02)
These trends are reflected in the changes of CGI
(Table 3). Byy the eighth week 90% of the acutely ill had
achieved CGI status of 1 or 2, while 66.6% and 76.9%,
respectively, of the treatment resistant long stays and short
stays had shifted to CGI status of 1-3.
Improvement in Hamilton Depression Rating Scale
scores at intervals: Olanzapine proved to be a highly
potent and rapidly acting antidepressant drug, even though
it is marketed as an antipsychotic drug.
There was a drastic reduction in mean HDRS scores
from 31.5 (SD 6.2) at intake, through 4.9 (SD 7.2) at the
second week, and 3.5 (SD 6.6) at the third week, to 1.8(SD
5.4) at the fourth week.  The only patient who remained
with any severe symptoms of depression after the fourth
week was a treatment resistant obsessive compulsive
patient.  Highly significant improvement in depression
scores evident at the second week (63.6% had fully
recovered and 3 or 27.3% others scored)(9-15), was
improved upon at the sixth week when all the eight
primarily depressed patients still remaining in the study
had achieved full clinical recovery.  It is to be noted that
most of these patients had severe psychomotor retardation,
with strong suicidal ideation.
In all these indices of efficacy, there were no significant
racial differences in psychopathological symptoms scores
at all the intervals of assessment.
Experience of effectiveness of drug dosages: It was
found that, treatment resistant schizophrenics and manic
subjects would require at least 20mg daily during the
active phase of treatment. Of the treatment resistant
schizophrenics, those who did very well (CGI, 1 or 2)
would appear to require about 15mg daily, while those
who responded at the CGI level of 3 or 4 would definitely
require at least 20mg daily.
Of the six long-stay neuroleptic treatment cases who
were tried on 30mg daily for four weeks, two showed no
significant improvement, three showed remarkable
improvement (CGI levels moved at least two points
positively), while one subject (with mild mental retardation)
only showed enhanced cognitive functioning and emotional
warmth.
It appears, therefore, that the 20mg maximum dosage
set by the manufacturers applies mainly to the acutely ill
psychotic subjects. Certainly, the recommended 7.5mg
daily, maintainance dosage is of no use to neuroleptic
treatment resistant cases. Also the NTRS cases should be
tried on at least 30mg daily before they can be pronounced
as non-responding.
Patients who recovered from depression and OCD
did quite well on a follow up dose of 5-l0mg nocte daily
dose.
Safety profiles: (i) Patients with epilepsy tolerated the
drug without increase of seizure frequency. Patients who
received OLZ in the two weeks after ECT, did not
experience post- ECT seizure; (ii) One 52-year old man
with heart failure and symptoms of severe depression,
responded well to 10mg olz, without adverse ECG effects;
(iii) One 25-year old man took 41 tablets of 5mg olz that
is, 205mg in a suicidal bid. ECG showed no abnormal
tracings, and there were no untoward effects; (iv) A 77-
year old lady who had had two episodes of CVA, developed
disruptive symptoms of delusional disorder. She tolerated
10-15mg of olz very well and; (v) One 45-year old
treatment resistant long-stay schizophrenic has had a
psoriasis-like skin lesion for several years, which showed
little or no response to treatment. While on OLZ only,
there was remarkable improvement in his skin condition
Leucopaenia in two subjects. Pre-olz: The result of
blood tests for two long-stay treatment resistant
schizophrenics (one male, 74-year old and one female, 52-
year old) showed that they had very low white blood cell
counts in the pre-treatment sample. The female also had
anaemia and hepato-splenomegaly, while the old man had
non- insulin dependent diabetes melitus. Repeated
sampling for leucocyte count in the period of three months
when they were on OLZ showed that, though they had no
significant remission of psychotic symptoms, their
leucocyte count actually improved significantly.
Extrapyramidal side effects: Two late middle aged
ladies and one elderly man with Pre-Olz mild levels of
tardive dyskinesia, experienced an intensification of their
dyskinesia, and tremors when OLZ was commenced. But
one 25-year old female with akathisia, was no longer
experiencing it. None of the six subjects who received
30mg OLZ showed any side effects. Two subjects had
grotesque abnormal body movements, ostensibly tardive
dystonia from years of neuroleptic treatment. They had
full clinical remission of psychosis and a significant
reduction in abnormal movements.
In other words, inspite of the fact that patients did not
receive concomitant anticholinergic medication, there were
no extrapyramidal features among subjects who did not
have them pre-olz.
Two girls (17 and 20 years) experienced amenorrhoea:
For one of them (on 5mg olz) menstruation returned at the
end of the third month while still on olz. For the second one
(on olz 10mg) menstruation quickly returned when she
stopped olz, as she had achieved full clinical recovery.
Weight gain was experienced by most patients,
especially out-patients: Weight gain was usually evident
at least by the sixth week of treatment. For the in-patients,
the nurses controlled this problem by placing the patients
on “reduction diet”; so that on the whole, the in-patients
did not complain about weight gain. One tall athletic built
young man’s weight increased from 90kg to 100kg in
three months of olz 10mg daily.
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Only one 36-year old lady showed mildly elevated
liver enzymes level at the third week of treatment. This
lady had used olz for at least six months, and the liver
enzymes have since normalised.
Impairment of consciousness and cognitive
functioning: The first remarkable feature of OLZ treatment
was that, patients who experienced insomnia while on a
combination of high dose classical neuroleptics, did sleep
soundly on just 20mg olz nocte.
However, in the day time, they had clear consciousness
and did not have the tired, day - time sommolent look that
is characteristic of patients on high levels of neuroleptics.
The subjects had high levels of concentration and attention
in the day time. OLZ seemed to have beneficient effects on
cognitive functioning on two schizophrenia - like cases
with brain damage.
DISCUSSION
The cohort was typical of the broad range of severe
mentally ill patients that we treat in our facility in Fiji, with
a broad age range and diagnostic categories. In particular,
the admixture of races in the sample is a fair representation
of the multi- racial nature of the country. In addition, we
had the opportunity to observe these patients for over a
period of one year on follow up, several months after many
of the subjects had stopped using the drug.
A major limitation of the study is that we were operating
with serious constraints of drug supply. The situation of
limitation of drug supply was even more problematic for
the out-patients whose relatives bought the drug. The high
purchasing cost of the drug was always a cause of complaints
by these relatives. Other limitations are the small sample
size and the open-label nature of the study which could lead
to bias in ratings, especially as the same worker did all the
assessments. In order to overcome this bias, data were
presented to show actual clinical recovery (CGI).
Efficacy profiles: Clearly, OLZ was proven to be a
highly potent antipsychotic drug among this cohort of
patients with a wide variety of severe psychiatric conditions.
Of particular interest is the finding that by the 8th week, 13
(48.l%) of 27 long-stay neuroleptic treatment resistant
patients achieved full clinical recovery (ie. CGI, 1 or 2), a
finding comparable to the best clinical outcome noted for
clozapine for a similar category of patients (l9). A Spanish
group (13), using efficacy indices of ≥35% decrease in
symptoms and CGI severity ≤4, in a trial of OLZ on 25
treatment refractory schizophrenics, found that 36%
achieved this response at six weeks, and 48% at six
months. All the symptoms of severe psychiatric states
were beneficiently affected.
As far as this author is aware, this is one of the first
reports of the efficacy of OLZ, specifically on depression
and OCD.
The results of this study are in keeping with the
findings of previous controlled studies. Since the findings
of this study issue from a naturalistic clinical setting, the
results are more likely to be in line with practical daily
clinical experience. The open label nature of the study
does not detract from the quality of the work, because
majority of the patients acted as their own controls, since
they had been on treatment with high dose neuroleptics for
several years in hospital.
With the small number of OCD cases  involved in this
study, the effect of OLZ on this condition encourages a
trial with a large sample size.
The efficacy of Olz in the treatment of depressive
symptoms among schizophrenics has been examined in
two controlled studies(3,7). Olz treated patients had
significantly greater reduction in PANSS depression item
and the Montgomery - Asberg Depression Rating Scale
(MADRS), compared with schizophrenics treated with
haloperidol and risperidone. The antidepressant effect
was maintained during the subsequent maintainance period.
Further proof of thymoleptic properties of Olz comes from
studies of patients with schizoaffective disorder, psychotic
depression and treatment - refractory depression(11,12) .
The wide ranging clinical effectiveness of OLZ is
most probably explained by its pleotropic effect. For
instance, the density of 5HT2A receptors has been reported
to be increased among patients with major depression.
Accordingly, OLZ, as a potent 5-HT2A antagonist, may
have acted on these sites, similar to the action of a classical
antidepressant such as nefazodone(20). The most
interesting aspect of the antidepressant effect of OLZ is
that it relieves depression at a median dose (10mg) much
earlier than the classical antidepressant drugs. The mood
related findings in this study are relevant because the
classical neuroleptics rather tend to be depressogenic(3).
Safety profiles: The most relevant side effects of OLZ
for this group of patients turned out to be weight gain and
high purchasing cost. Otherwise OLZ achieved the
distinction of being able to send severely disturbed patients
to sleep at night, without a residue day-time drowsiness,
impairment of cognitive functioning, and extrapyramidal
reactions. As the study progressed the author gained the
impression that OLZ is a fairly “clean” molecule among
antipsychotic drugs. Also, cognitive function was rather
enhanced, in line with the findings of a recent Canadian
study in which olanzapine had a significantly superior
beneficient effect on cognitive functioning among
schizophrenics compared with risperidone and
haloperidol(11).
In conclusion, with all these properties, OLZ, thus far,
can be said to be a safe drug, which has merited the
credentials of an “atypical” antipsychotic. An important
experience gained from this study is that, no matter how
effective a drug is in relieving symptoms, serious attention
to psychosocial factors is crucial in the overall treatment
outcome.
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